c19early.org COVID-19 treatment researchCOVID-19 treatments

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19

Wilkerson et al., NCT04705597, NCT04705597, May 2022
Late treatmentDouble-blind RCT · NCT04705597 · 194 patients · USA
Asapiprant for COVID-19
Wilkerson et al. NCT04705597 · May 2022
Higher mortality and ICU admission
Not statistically significant · p = 0.21 (mortality) and p = 0.37 (ICU admission)
RCT 194 hospitalized COVID-19 patients showing no significant differences with asapiprant (BGE-175).
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
OutcomeImprovementEffect · pTreatmentControl
risk of death 63.3% higher · RR 1.63 · p = 0.21 63.3% higherRR 1.63p = 0.21 16 of 96 (16.7%) 10 of 98 (10.2%) treatment 16 of 96 (16.7%), control 10 of 98 (10.2%)
risk of ICU admission 32.1% higher · RR 1.32 · p = 0.37 32.1% higherRR 1.32p = 0.37 22 of 96 (22.9%) 17 of 98 (17.3%) treatment 22 of 96 (22.9%), control 17 of 98 (17.3%)
risk of severe case 24.0% higher · RR 1.24 · p = 0.36 24.0% higherRR 1.24p = 0.36 34 of 96 (35.4%) 28 of 98 (28.6%) treatment 34 of 96 (35.4%), control 28 of 98 (28.6%)
time to improvement 33.3% higher · relative time 1.33 · p = 0.17 33.3% higherrelative time 1.33p = 0.17 8.0 [6.0-10.0] n=96 6.0 [5.0-9.0] n=98 treatment 8.0 [6.0-10.0] n=96, control 6.0 [5.0-9.0] n=98
risk of progression 23.0% higher · RR 1.23 · p = 0.43 23.0% higherRR 1.23p = 0.43 31 of 94 (33.0%) 26 of 97 (26.8%) treatment 31 of 94 (33.0%), control 26 of 97 (26.8%)death or respiratory failure

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Wilkerson et al., 19 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, critical, trial NCT04705597 (history). Contact: patrick@bioagelabs.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective